Experimental investigation of the role of endothelin-1 in idiopathic portal hypertension

Journal of Gastroenterology and Hepatology (Australia)

Volumn 22, Issue 7, 2007, Pages 1134-1140

  Yamaguchi, Emi ^a   Yamanoi, Akira ^a   Ono, Takashi ^a   Nagasue, Naofumi ^a  

^a SHIMANE UNIVERSITY   (Japan)

Author keywords

Arsenic; B lymphocyte; Endothelin 1; Interferon gamma; Lipopolysaccharide; Monocyte derived macrophage; Portal hypertension

Indexed keywords

ARSENATE SODIUM; ARSENITE SODIUM; ENDOTHELIN 1; GAMMA INTERFERON; LIPOPOLYSACCHARIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; B LYMPHOCYTE; CELL TYPE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MACROPHAGE; MALE; MONOCYTE; NONHUMAN; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; SPLEEN; SUPERNATANT; T LYMPHOCYTE;

EID: 34347403731     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2006.04822.x     Document Type: Article

References (35)

1. Tsujimura T, Nakanishi T, Sano H, Takeuchi T. Idiopathic portal hypertension associated with polyclonal hyperimmunoglobulinemia. A case report and review of the literature. Acta Pathol. Jpn. 1987 37 : 1645 51.
2. Nakanuma Y, Nonomura A, Hayashi M et al. Pathology of the liver in "idiopathic portal hypertension" associated with autoimmune disease. The Ministry of Health and Welfare Disorders of Portal Circulation Research Committee. Acta Pathol. Jpn 1989 39 : 586 92.
3. Tokushige K, Komatsu T, Ohzu K, Yamauchi K, Obata H. A defective autologous mixed lymphocyte reaction in patients with idiopathic portal hypertension. J. Gastroenterol. Hepatol. 1992 7 : 270 3.
4. Saito K, Nakanuma Y, Takegoshi K et al. Non-specific immunological abnormalities and association of autoimmune diseases in idiopathic portal hypertension. A study by questionnaire. Hepato-gastroenterology 1993 40 : 163 6.
5. Shirai T, Hirose S, Futagawa S, Tokushige K, Aoshiba T, Yamauchi K. Abnormalities in T-cells in idiopathic portal hypertension. In : Futagawa S, ed. 1992 Report on the Research Committee on Aberrant Portal Hemodynamics Tokyo : Ministry of Health and Welfare, 1993 67 9 (in Japanese).
6. Tokushige K, Hirose S, Nishimura H et al. Abnormal T cell activation and skewed T cell receptor Vβ repertoire usage in Japanese patients with idiopathic portal hypertension. Clin. Immunol. Immunopathol. 1995 75 : 206 13.
7. Mori K, Ishimura E, Goto H et al. Idiopathic portal hypertension associated with high serum titer of autoantibodies and liver dysfunction. J. Gastroenterol. 1996 31 : 123 8.
8. Inagaki H, Nonami T, Kawagoe T et al. Idiopathic portal hypertension associated with systemic lupus erythematosus. J. Gastroenterol. 2000 35 : 235 9.
9. Tsuneyama K, Harada K, Katayanagi K et al. Overlap of idiopathic portal hypertension and scleroderma: report of two autopsy cases and a review of literature. J. Gastroenterol. Hepatol. 2002 17 : 217 23.
10. Sugita S, Ohnishi K, Saito M, Okuda K. Splanchnic hemodynamics in portal hypertensive dogs with portal fibrosis. Am. J. Physiol. 1987 252 : G748 54.
11. Kono K, Ohnishi K, Omata M et al. Experimental portal fibrosis produced by intraportal injection of killed nonpathogenic Escherichia coli in rabbits. Gastroenterology 1988 94 : 787 96.
12. Sugita S, Ohnishi K, Iida S, Nomura F, Okuda K. Histological changes in the liver and portal hypertension subsequent to repeated intraportal injections of killed E. Coli in the dog. Liver 1988 8 : 1 9.
13. Umeyama K, Yamashita T, Yoshikawa K. [Etiology of idiopathic portal hypertension (IPH) - the role of immunological mechanism in IPH.] Nippon Geka Gakkai Zasshi 1992 93 : 400 12 (in Japanese with English abstract).
14. Datta DV, Mitra SK, Chhuttani PN, Chakravarti RN. Chronic oral arsenic intoxication as a possible aetiological factor in idiopathic portal hypertension (non-cirrhotic portal fibrosis) in India. Gut 1979 20 : 378 84.
15. Datta DV. Arsenic and non-cirrhotic portal hypertension (Letter). Lancet 1976 1 : 433.
16. Huet PM, Guillaume E, Cote J, Legare A, Lavoie P, Viallet A. Noncirrhotic presinusoidal portal hypertension association with chronic arsenical intoxication. Gastroenterology 1975 68 : 1270 7.
17. Morris JS, Schmid M, Newman S, Scheuer PJ, Path P, Sherlock S. Arsenic and non-cirrhotic portal hypertension. Gastroenterology 1974 66 : 86 94.
18. Rockey D. The cellular pathogenesis of portal hypertension: stellate cell contractility, endothelin, and nitric oxide. Hepatology 1997 25 : 2 5.
19. Yanagisawa M, Kurihara H, Kimura S et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988 332 : 411 15.
20. Inoue A, Yanagisawa M, Kimura S et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. USA 1989 86 : 2863 7.
21. Asbert M, Gines A, Gines P et al. Circulating levels of endothelin in cirrhosis. Gastroenterology 1993 104 : 1485 91.
22. Gerbes AL, Moller S, Gülberg V, Henriksen JH. Endothelin-1 and -3 plasma concentrations in patients with cirrhosis: role of splanchnic and renal passage and liver function. Hepatology 1995 21 : 735 9.
23. Uchihara M, Izumi N, Sato C, Marumo F. Clinical significance of elevated plasma endothelin concentration in patients with cirrhosis. Hepatology 1992 16 : 95 9.
24. Futagawa S, Beppu N, Watanabe S Annual Report of the Research Committee on Portal Hemodynamics Abnormalities. Tokyo : Ministry of Health and Welfare, 1998 59 60 (in Japanese).
25. Kamath PS, Tyce GM, Miller VM, Edwards BS, Rorie DK. Endothelin-1 modulates intrahepatic resistance in a rat model of noncirrhotic portal hypertension. Hepatology 1999 30 : 401 7.
26. Kamath PS, Carpenter HA, Lloyd RV et al. Hepatic localization of endothelin-1 in patients with idiopathic portal hypertension and cirrhosis of the liver. Liver Transpl. 2000 6 : 596 602.
27. Nagasue N, Dhar DK, Yamanoi A et al. Production and release of endothelin-1 from the gut and spleen in portal hypertension due to cirrhosis. Hepatology 2000 31 : 1107 14.
28. Falkoff RJ, Muraguchi A, Hong JX, Butler JL, Dinarello CA, Fauci AS. The effects of interleukin 1 on human B cell activation and proliferation. J. Immunol. 1983 131 : 801 5.
29. Ehrenreich H, Anderson RW, Fox CH, Rieckmann P, Hoffman GS, Travis WD. Endothelins, peptides with potent vasoactive properties, are produced by human macrophages. J. Exp. Med. 1990 172 : 1741 8.
30. Boyer JL, Sen Gupta KP, Biswas SK et al. Idiopathic portal hypertension. Comparison with the portal hypertension of cirrhosis and extrahepatic portal vein obstruction. Ann. Intern. Med. 1967 66 : 41 68.
31. Sama SK, Bhargava S, Gopi Nath N et al. Noncirrhotic portal fibrosis. Am. J. Med. 1971 51 : 160 9.
32. Chanez P, Vignola AM, Albat B et al. Involvement of endothelin in mononuclear phagocyte inflammation in asthma. J. Allergy Clin. Immunol. 1996 98 : 412 20.
33. Holst O, Ulmer AJ, Brade H, Flad HD, Rietschel ET. Biochemistry and cell biology of bacterial endotoxins. FEMS Immunol. Med. Microbiol. 1996 16 : 83 104.
34. Peavy DL, Adler WH, Smith RT. The mitogenic effects of endotoxin and staphylococcal enterotoxin B on mouse spleen cells and human peripheral lymphocytes. J. Immunol. 1970 105 : 1453 8.
35. Kuroki T, Morikawa H, Kawata N, Nishiguchi S, Shiomi S, Kaneda K Annual Report of the Research Committee on Portal Hemodynamics Abnormalities. Tokyo : Ministry of Health and Welfare, 1997 29 30 (in Japanese).